Roche has announced results from its Phase IIb PADOVA study evaluating prasinezumab in patients with early-stage Parkinson’s disease. While the primary endpoint of time to confirmed motor progression did not reach statistical significance, the drug demonstrated promising trends in several secondary and exploratory endpoints.   The study, which enrolled 586 patients, assessed the efficacy and safety of prasinezumab over 18 months. While the primary endpoint was not met, a pre-specified analysis...